Remove topics congressional-oversight
article thumbnail

Will California Eliminate Anonymous Web Browsing? (Comments on CA AB 2273, The Age-Appropriate Design Code Act)

Technology & Marketing Law Blog

Third, this bill reaches topics well beyond children’s privacy. Instead, the bill repeatedly implicates general consumer protection concerns and, most troublingly, content moderation topics. ” The scope of this taskforce likely exceeds privacy topics. We don’t do “A-for-Effort” laws in the U.S.,

Privacy 138
article thumbnail

What is Blockchain Technology and has it been Patented?

Biswajit Sarkar Copyright Blog

Consumers would face lesser fees and there would be better regulatory oversight along with better preparedness against financial frauds. This technology would thus alter the way banks transact worldwide by making financial transactions more secure and accessible and lowering operating costs.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

What is Blockchain Technology and has it been Patented?

Biswajit Sarkar Copyright Blog

Consumers would face lesser fees and there would be better regulatory oversight along with better preparedness against financial frauds. This technology would thus alter the way banks transact worldwide by making financial transactions more secure and accessible and lowering operating costs.

article thumbnail

What is Blockchain Technology and has it been Patented?

Biswajit Sarkar Copyright Blog

Consumers would face lesser fees and there would be better regulatory oversight along with better preparedness against financial frauds. This technology would thus alter the way banks transact worldwide by making financial transactions more secure and accessible and lowering operating costs.

article thumbnail

Biosimilars 2021 Year in Review

Fish & Richardson Trademark & Copyright Thoughts

The letter discusses the BPCIA and the Hatch-Waxman Act frameworks (for small molecule drugs) and sets forth several topics for USPTO’s consideration and further discussion: engagement between FDA and USPTO to increase efficiencies, possible misuse of the patent system (e.g., 9, 2022); FDA Biosimilars Approvals, Biosimilars Council (Sept.